Andy Pasternak Sells 4,850 Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP) Stock

Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) EVP Andy Pasternak sold 4,850 shares of the firm’s stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $82.57, for a total value of $400,464.50. Following the transaction, the executive vice president now owns 34,047 shares in the company, valued at $2,811,260.79. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Andy Pasternak also recently made the following trade(s):

  • On Friday, June 10th, Andy Pasternak sold 762 shares of Horizon Therapeutics Public stock. The stock was sold at an average price of $85.36, for a total value of $65,044.32.

Horizon Therapeutics Public Price Performance

HZNP opened at $82.97 on Friday. The stock has a fifty day simple moving average of $84.68 and a two-hundred day simple moving average of $93.95. The company has a current ratio of 3.57, a quick ratio of 3.30 and a debt-to-equity ratio of 0.53. The company has a market cap of $19.07 billion, a price-to-earnings ratio of 22.73, a price-to-earnings-growth ratio of 1.18 and a beta of 1.17. Horizon Therapeutics Public Limited has a 12-month low of $78.40 and a 12-month high of $120.54.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.15 by $0.19. The business had revenue of $885.25 million during the quarter, compared to the consensus estimate of $866.39 million. Horizon Therapeutics Public had a return on equity of 32.08% and a net margin of 22.87%. The firm’s quarterly revenue was up 158.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.03 earnings per share. Research analysts predict that Horizon Therapeutics Public Limited will post 5.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Horizon Therapeutics Public

A number of institutional investors have recently added to or reduced their stakes in the company. Capital International Investors purchased a new stake in shares of Horizon Therapeutics Public in the first quarter worth $744,453,000. Norges Bank purchased a new stake in shares of Horizon Therapeutics Public in the fourth quarter worth $250,526,000. Marshall Wace LLP grew its stake in shares of Horizon Therapeutics Public by 3,782.6% in the fourth quarter. Marshall Wace LLP now owns 1,656,679 shares of the biopharmaceutical company’s stock worth $178,522,000 after acquiring an additional 1,614,010 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of Horizon Therapeutics Public in the fourth quarter worth $149,271,000. Finally, 1832 Asset Management L.P. grew its stake in shares of Horizon Therapeutics Public by 1,492.5% in the fourth quarter. 1832 Asset Management L.P. now owns 1,406,500 shares of the biopharmaceutical company’s stock worth $152,084,000 after acquiring an additional 1,318,180 shares during the last quarter. Institutional investors own 88.39% of the company’s stock.

Analyst Ratings Changes

HZNP has been the topic of several recent research reports. SVB Leerink initiated coverage on Horizon Therapeutics Public in a research report on Monday, May 23rd. They set a “market perform” rating and a $95.00 price target on the stock. Oppenheimer restated a “buy” rating and set a $140.00 price target on shares of Horizon Therapeutics Public in a research report on Friday, July 8th. UBS Group reduced their target price on Horizon Therapeutics Public from $139.00 to $137.00 and set a “buy” rating on the stock in a research note on Tuesday, July 5th. Finally, Wells Fargo & Company restated a “buy” rating and set a $133.00 target price on shares of Horizon Therapeutics Public in a report on Friday, April 8th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.10.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Recommended Stories

Insider Buying and Selling by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.